| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 11 Nov 2025 | 5 Nov 2025 |
| Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 inter alia to consider and approve Prior Intimation of Board Meeting scheduled to be held on November 11 2025 for approving Unaudited Limited Reviewed Financial Results for Quarter II and half year for Financial Year 2025-26 Unaudited Limited Reviewed Financial Results for the Q-2 & Half Year ended on September 30, 2025 (As Per Bse Announcement dated on 11/11/2025) | ||
| Board Meeting | 12 Aug 2025 | 5 Aug 2025 |
| Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve approval of Unaudited Limited Reviewed Financial Results (Standalone & Consolidated) of the Company for Quarter-1 of F.Y.2025-26 ended on June 30 2025. Outcome of Board Meeting inter-alia for consideration and approval of Financial Results for the Q-1 of F.Y. 2025-26, ended on June 30, 2025. (As Per BSE Announcement Dated on: 12/08/2025) | ||
| Board Meeting | 26 May 2025 | 20 May 2025 |
| Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 inter alia to consider and approve the Audited Financial Results (Standalone & Consolidate) of the company for the Quarter-IV and Financial Year ended on March 31 2025 Outcome of Board Meeting for considering and approving Annual Audited Financial Results for the quarter and F.Y. ended on March 31, 2025 (As per BSE Announcement Dated on 26/05/2025) | ||
| Board Meeting | 12 Feb 2025 | 6 Feb 2025 |
| Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve the un-audited Limited Reviewed Financial Results for the Quarter III of Financial Year 2024-25 ended on December 31 2024. Outcome of Board meeting held for ,inter alia, consideration and approval of Unaudited Limited Reviewed Financial Results (Standalone and Consolidated) for the Quarter ended December 31, 2024. (As Per BSE Announcement Dated on: 12/02/2025) | ||
At around 12.53 PM, Orchid Pharma was trading 5% higher at ₹740.40, against the previous close of ₹705.15 on NSE.
The inspection raised, seven minor observations none related to data integrity, and therefore, the facility remains compliant under stringent regulatory standards.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
